- Ring The Bell
- Posts
- 🏀 Why The Market Could Bounce Back
🏀 Why The Market Could Bounce Back
Plus, how to avoid holding the bag, and more
You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.
Happy Wednesday! Sharp market declines can rattle investors, but history suggests they often set the stage for strong rebounds. Here’s what past data reveals about post-selloff recoveries — and how investors can position for the bounce. Also, learn how to avoid getting sucked into bad bets.
—Josh Enomoto
Plus, if you’re interested in a new approach to addressing rare diseases, check out today’s sponsor.
MARKET RECAP
Yesterday: Stocks fell Tuesday as new U.S. tariffs took effect, weighing on financial and industrial stocks. Trade tensions escalated with China and Canada imposing retaliatory duties, while bond yields edged higher as markets adjusted Fed rate cut expectations. Investors now turn to upcoming economic data and policy signals for further direction.
On Our Radar: After reviewing this morning’s ADP employment numbers, analysts will turn to tomorrow’s initial jobless claims for additional economic gauges. On the earnings front, semiconductor specialist Marvell Technology will disclose its results following the closing bell.
TOP STORY
Markets are grappling with uncertainty as investors assess the fallout from renewed trade tensions and the broader economic landscape.
SPONSORED CONTENT
Last year was an important one for Soligenix (NASDAQ: SNGX), as the firm achieved several milestones. Soligenix announced that their leading product, HyBryte™, a potential treatment for cutaneous T-cell lymphoma (CTCL), a rare, chronic and treatable type of non-Hodgkin lymphoma affecting the skin, demonstrated continued improvement in treated patients and their lesions, even after stopping treatment.
Also, regarding HyBryte, in October 2024, Soligenix announced that the Hong Kong Patent Office had granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin." Synthetic hypericin is an active ingredient in HyBryte. Soligenix also received a similar patent in Europe.
Entering 2025, the firm says it is hoping to continue building on that momentum. To learn more about Soligenix, click here.
This is a paid ad. Please see 17b disclosure here for more information.
FIVE ZINGERS
Heightened Stakes: Canadian Prime Minister Justin Trudeau announced retaliatory tariffs on U.S. imports. Not surprisingly, President Donald Trump threatened even tougher action.
High Roller: Cathie Wood's flagship ARK Innovation ETF has been making big moves, even drawing sharp criticism. Discover the acquisition that has been so contentious.
Falling Flat: The crypto sector's brief rally encountered challenges due to concerns over the Trump tariffs. Learn about the prospects of digital assets in this new paradigm.
Tail Spin: Drone weapons manufacturer AeroVironment posted Q3 revenue of only $167.6 million, missing the consensus view of $196.37 million. Read management's explanation for the shortcoming.
Fully Charged: EV infrastructure specialist ChargePoint posted revenue of $101.88 million, edging out expectations. Here are the other key metrics the company disclosed.
SPECIAL OFFER
Editor’s Note: Every Tuesday, Benzinga Edge members receive the Under the Radar pick, detailing a very profitable stock or market trend that no one’s talking about. Here’s a sneak peek at yesterday’s:
Wall Street and the financial media love to hype certain stocks. When a company is firing on all cylinders, you'll hear about it everywhere—every analyst has a buy rating, hedge funds are loading up and the media can't stop singing its praises. It seems like an easy trade. But if you've been in the markets long enough, you know that when everyone is on the same side of a trade, danger isn't far behind.
A stock that's loved by all often runs up fast. Institutional buying creates a feedback loop—funds pile in, momentum picks up and the price keeps climbing. The story seems bulletproof. This is how bubbles form.
The problem is that when expectations are sky-high, reality has a way of disappointing. Even a small earnings miss or a change in macro conditions can turn the tide. When a stock is priced for perfection, there's no room for error. And when things go south, they go south fast.
Here's the real danger: when a stock is overcrowded, everyone who wants to own it already does. There are no new buyers to support the price. So when bad news hits, institutions start heading for the exits. And when big money moves, they don't tiptoe out the door—they dump shares, and liquidity evaporates. Prices collapse under their own weight.
Get all the details from yesterday’s Benzinga Edge-exclusive Under the Radar report. Click here to get a sneak peek.
SPECIAL OFFER
The market is shifting, but short-term traders have a major edge. Join Matt Maley live TONIGHT, Wednesday, March 5, at 6 PM ET as he shares his top trading setups for March—covering inflation-driven moves, rate expectations and high-momentum stocks. Click here to reserve your spot today!
BEFORE YOU GO
Were you forwarded this email? Click here to subscribe.
And be sure to check out our other newsletters:
Future Finance: Where fintech, crypto and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.
Cannabis Daily: A must-read daily briefing for cannabis investors, operators and enthusiasts. Join our list of industry veterans to jump start your morning. Subscribe here.
Advisor: Tailor-made for Financial Advisors, this weekly newsletter has industry-specific insights, analysis and news. Subscribe here.
Tech Trends: Get the inside scoop on AI, the hottest gadgets and mind-blowing tech trends. Subscribe here.